

NCT ID	NCT05425940
Title	Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)
Phase	Phase 3
Date Added	2022-06-21
Location	Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nebraska, United States New Mexico, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Virginia, United States Washington, United States Australia Belgium France Germany Hong Kong Hungary New Zealand Poland Portugal Singapore South Korea Spain Taiwan Thailand United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq
Tags	MSS/ MMRp

NCT ID	NCT05409417
Title	Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status
Phase	Phase 2
Date Added	2022-06-08
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Unknown status
Drugs	Bevacizumab, cetuximab, FOLFOX, Tislelizumab, XELOX

Tags	MSS/ MMRp
NCT ID	NCT05382741
Title	Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
Phase	Phase 2
Date Added	2022-05-19
Location	Italy
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules, Imfinzi, Stivarga
Tags	MSS/ MMRp
NCT ID	NCT05382442
Title	A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2022-05-19
Location	California, United States Virginia, United States China
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	5-Fluorouracil, Bevacizumab, capecitabine, Irinotecan, Leucovorin, oxaliplatin
Tags	MSS/ MMRp
NCT ID	NCT05350917
Title	Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
Phase	Phase 2
Date Added	2022-04-28
Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	Tislelizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05349890
Title	Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Phase	Phase 1
Date Added	2022-04-27
Location	Oregon, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	CDX-1140, Pembrolizumab, Keytruda
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05333809
Title	Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

Phase	Phase 2
Date Added	2022-04-19
Location	
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	Disitamab vedotin, Pembrolizumab, Keytruda
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT05328908
Title	A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
Phase	Phase 3
Date Added	2022-04-14
Location	Arkansas, United States California, United States Connecticut, United States Florida, United States Georgia, United States Idaho, United States Indiana, United States Massachusetts, United States Michigan, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Virginia, United States Wisconsin, United States Argentina Australia Austria Belgium Canada Chile China Czechia France Germany Italy Japan Korea, Republic of Netherlands Poland Puerto Rico Singapore Spain Sweden Switzerland Taiwan
Prior IO Allowed	No
CRC-directed	Yes
Status	Terminated
Drugs	Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT05319314

Title	GCC19CART for Patients With Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2022-04-08
Location	California, United States Colorado, United States Massachusetts, United States Michigan, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	GCC19CART
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT05308446
Title	Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
Phase	Phase 2
Date Added	2022-04-04
Location	Arizona, United States California, United States Colorado, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States New Hampshire, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Puerto Rico
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo
Tags	MSS/ MMRp